Guidelines issued by the Stroke Council of the American Heart Association and published in Circulation and Stroke recommend use of Altace (ramipril) in people with diabetes who are at risk for stroke. These recommendations are based on the Heart Outcomes Prevention Evaluation study, which showed that people with diabetes can reduce their risk of stroke by 33 percent, even if they are taking other medications. People with diabetes are two to four times more likely to suffer from heart disease. Altace, an ACE inhibitor, is marketed by Monarch Pharmaceuticals.
COPYRIGHT 2001 Lebhar-Friedman, Inc.
COPYRIGHT 2001 Gale Group